IDEAS COME FROM THE HEARTArena Pharmaceuticals is expanding our capabilities to study acute heart failure and conditions of impaired microvascular circulation.
ABOUT ACUTE HEART FAILURE
Acute heart failure (AHF) is a life-threatening condition characterized by the worsening or onset of new symptoms of heart failure that require emergency treatment and often hospitalization. In this setting, re-establishing adequate cardiac performance is essential for clinical stabilization and the successful and rapid recovery of the patient. New therapeutic approaches are desperately needed, especially for the most vulnerable patient profiles.
ABOUT MICROVASCULAR OBSTRUCTION
Microvascular obstruction (MVO) is a condition with high unmet medical need characterized by the failure to achieve adequate blood flow in the coronary microcirculation despite resolution of large coronary artery blockage by percutaneous coronary intervention (PCI, also known as angioplasty/coronary stenting). While PCI is a common and essential treatment for coronary artery disease, it also results in activation of platelets and release of serotonin, which mediates platelet aggregation and vasoconstriction in the coronary microcirculation, and is thought to contribute to MVO.
ABOUT RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
Raynaud’s phenomenon secondary to systemic sclerosis (SSc-RP) is a debilitating condition with high unmet medical need in patients with damaged blood vessels due to systemic sclerosis. It is characterized by an exaggerated constriction of the small blood vessels in the hands and feet in response to cold temperature or emotional stress. These episodes result in prolonged and significant decreases in blood flow leading to painful attacks, ulcers, gangrene, and even amputation of the fingers and toes. Exposure of the extremities to cold results in activation of platelets and release of serotonin, which mediates platelet aggregation and vasoconstriction in the microcirculation, and is thought to contribute to this condition.